Management of hormone receptor-positive, HER2-negative early breast cancer

Elaine M. Walsh, Karen L. Smith, Vered Stearns

Research output: Contribution to journalReview articlepeer-review


The majority of breast cancers are diagnosed at an early stage and are hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative. Significant advances have been made in the management of early stage HR-positive, HER2-negative breast cancer, resulting in improved survival outcomes. In this review, we discuss important factors to consider in the management of this disease. In particular, we discuss the role of adjuvant endocrine therapy, specific endocrine therapy agents, the duration of adjuvant endocrine therapy, treatment-related side effects, and the role of genomic assays and other biomarkers when considering treatment recommendations for individuals with HR-positive, HER2-negative early breast cancer. Finally, we address emerging data to individualize therapeutic decision-making and provide future considerations.

Original languageEnglish (US)
Pages (from-to)187-200
Number of pages14
JournalSeminars in oncology
Issue number4
StatePublished - Aug 2020


  • Breast cancer
  • Endocrine therapy
  • Hormone receptor

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'Management of hormone receptor-positive, HER2-negative early breast cancer'. Together they form a unique fingerprint.

Cite this